The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application notesICC/IF: Use at an assay dependent dilution. Fixation in 4% paraformaldehyde in PBS for 20 min.
WB: Use at an assay dependent dilution. Predicted molecular weight: 29 kDa.
Not yet tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceFibroblast growth factors (FGFs) can stimulate the proliferation of mesenchymal, epithelial and neuroectodermal cells. FGF3 belongs to the heparin binding growth factors family. Members of the family include Acidic FGF (also known as aFGF or FGF 1), basic FGF (bFGF or FGF 2), FGF 3 (also known as Int2) and FGF 4 (also known as hst or Kaposi FGF). FGF 4 was first revealed to be an oncoprotein in Kaposi's sarcoma cells. Other family members include FGF 5, FGF 6, FGF 7 (keratinocyte growth factor, KGF), FGF 8 (AIGF), FGF 9 (GAF) and FGF 10. FGF3 is activated by proviral insertion of mouse mammary tumor virus (MMTV). FGF3 is responsible for most of breast malignancies.
Murine mammary tumor virus integration site (v int 2) oncogene homolog antibody
Murine mammary tumor virus integration site 2 antibody
Oncogene INT2 antibody
V INT2 murine mammary tumor virus integration site oncogene homolog antibody
References for Anti-FGF3 antibody [MSD1] (ab10830)
This product has been referenced in:
Xiao W et al. Upregulation of miR-31* Is Negatively Associated with Recurrent/Newly Formed Oral Leukoplakia. PLoS One7:e38648 (2012).
Read more (PubMed: 22719913) »
Giatromanolaki A et al. DEC1 (STRA13) protein expression relates to hypoxia- inducible factor 1-alpha and carbonic anhydrase-9 overexpression in non-small cell lung cancer. J Pathol200:222-8 (2003).
Read more (PubMed: 12754744) »